top of page

Product/

Indication

2023

2024

2025

2026

2027

LXM.1

Epilepsy

LXM.4

Rheumatoid Arthiritis

LXM.5

Parkinson's Disease

LXM.6

Treatment of Renal Cell Carcinoma

LXM.9

Antidepressants

LXM.10

Thromboembolism

LXM.11

Thromboprophylaxis

LXM.12

Prostate Carcinoma

2028 +

LXM.2

Diabetes/ Metabolic Syndrome

Pipeline Key

Product Development + Launch Timeline 

Laxxon has both an external pipeline and an in-house Advanced Patented Generic pipeline.

All products created with our SPID®-Technology manufacturing approach are patent protected, whether engineered in-house or with an external partner.

Laxxon - [screen printing (white)].png

Product Pipeline

Learn more about our internal and external pipelines

Wide array of Laxxon's 3D printed tablets

Laxxon has both an external pipeline and an in-house Advanced Patented Generic pipeline.

All products created with our SPID®-Technology manufacturing approach are patent protected, whether engineered in-house or with an external partner.

bottom of page